# US 12,016,886 B2 · Microvascular endothelial cell comprising a nucleic acid encoding an anti-TDP-43 fab

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,016,886 B2
- Document ID: US12016886B2
- Status: Granted
- Kind: B2
- Application number: 18/046,734
- Filed: 2022-10-14
- Published: 2023-08-10
- Granted: 2024-06-25
- Earliest claimed: 2018-11-06
- Assignees: ALSaTECH, Inc.
- Applicants: ALSaTECH, Inc.
- Inventors: Claude Nicolau; Claudine Kieda; Reynald Thinard; Ruth Greferath; Melanie Chevalier
- Web page: https://patentgrep.com/patent/US12016886B2

## CPC

- A61K 35/44: Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 16/18: against material from animals or humans
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C12N 5/0691: {Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels}
- C12N 15/85: for animal cells
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2317/50: characterized by immunoglobulin fragments
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/01: containing a localisation/targetting motif
- C07K 2319/02: containing a signal sequence
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates, in part, to cell-based gene therapies, including those targeting, by way of non-limiting example, TDP43 and Aβ aggregates, for the use in neurodegenerative disorders, including without limitation Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease, respectively.

## Claims

### Claim 1

A composition comprising a nucleic acid encoding a Fab directed against TDP43, the anti-TDP43 Fab comprising:
(i) a variable heavy domain (VH) comprising: the amino acid sequence of SEQ ID NO: 13 and complementarity-determining region (CDR) 1 having the amino acid sequence of SEQ ID NO: 19,
CDR2 having the amino acid sequence of SEQ ID NO: 20, and
CDR3 having the amino acid sequence of SEQ ID NO: 21; and
(ii) a variable light domain (VL) comprising: the amino acid sequence of SEQ ID NO: 14 and
CDR1 having the amino acid sequence of SEQ ID NO: 22,
CDR2 having the amino acid sequence of SEQ ID NO: 23, and
CDR3 having the amino acid sequence of SEQ ID NO: 24.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the anti-TDP43 Fab further comprises a signal peptide having the amino acid sequence of SEQ ID NO: 34 or SEQ ID NO: 35.

### Claim 3 (depends on 1)

An expression vector comprising the nucleic acid of claim 1.

### Claim 4 (depends on 3)

An isolated host cell comprising the expression vector of claim 3.

### Claim 5 (depends on 1)

A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

### Claim 6

An isolated microvascular endothelial cell (MEC) comprising a nucleic acid encoding a Fab directed against TDP43, the anti-TDP-43 Fab comprising:
(i) a variable heavy domain (VH) comprising: the amino acid sequence of SEQ ID NO:13 and complementarity-determining region (CDR) 1 having the amino acid sequence of SEQ ID NO:19, CDR2 having the amino acid sequence of SEQ ID NO:20, and CDR3 having the amino acid sequence of SEQ ID NO:21; and
(ii) a variable light domain (VL) comprising: the amino acid sequence of SEQ ID NO:14 and CDR1 having the amino acid sequence of SEQ ID NO:22, CDR2 having the amino acid sequence of SEQ ID NO:23, and CDR3 having the amino acid sequence of SEQ ID NO:24.

### Claim 7 (depends on 6)

The MEC of claim 6, wherein the MEC is a brain-derived MEC which homes to brain microvasculature and traffic and release the anti-TDP43 Fab past blood brain barrier (BBB).

### Claim 8 (depends on 6)

The MEC of claim 6, wherein the MEC is autologous, and wherein the MEC is derived from bone marrow, brain, CNS, heart, liver, or pancreas.

### Claim 9 (depends on 6)

The MEC of claim 6, wherein the nucleic acid comprises a CAG promoter that promotes expression in endothelial cells and/or an insulin sequence that promotes export of the anti-TDP43 Fab.

### Claim 10 (depends on 6)

The MEC of claim 6, wherein the anti-TDP43 Fab comprises a signal peptide having the amino acid sequence of SEQ ID NO: 34 or SEQ ID NO: 35.
